Statement: A patient in the primary trial had a vaginal fungal infection.
Primary_evidence: Adverse Events 1:   Total: 3/49 (6.12%)   Neutrophils/ANC *1/49 (2.04%)   Leukocytes *1/49 (2.04%)   Hypocalcemia *1/49 (2.04%)   Febrile neutropenia *1/49 (2.04%)   Left Ventricular Systolic Dysfunction *1/49 (2.04%)   Constipation *1/49 (2.04%)   Mucositis-oral *1/49 (2.04%)   Infection-oral thrush *1/49 (2.04%)   rash *1/49 (2.04%)